Home › Compare › CYJBY vs ABBV
CYJBY yields 3.26% · ABBV yields 3.06%● Live data
📍 CYJBY pulled ahead of the other in Year 2
Combined, CYJBY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYJBY + ABBV for your $10,000?
Cargotec Corporation provides cargo and load handling solutions worldwide. It operates in three segments: Kalmar, Hiab, and MacGregor. The Kalmar segment offers cargo handling equipment and automated terminal solutions, software, and services for ports, terminals, distribution centers, and various industries; ship-toshore cranes, rubbertyred and rail-mounted gantry cranes, straddle and shuttle carriers, reachstackers, empty container handlers, terminal tractors, and forklift trucks, and automated guided vehicles; and automation systems, and Bromma spreaders, as well as maintenance contracts, technical support, spare parts, training, and crane upgrade services. The Hiab segment provides loader handling equipment under the HIAB, EFFER, and ARGOS brands; truck mounted forklifts under the MOFFETT and PRINCETON brands; forestry and recycling cranes under the LOGLIFT and JONSERED brands; hooklifts and skiploaders under the MULTILIFT brand; tail lifts under the ZEPRO, DEL, and WALTCO brands; HiConnect platform; and Hiab ProCare services and HiVision crane operating system. The MacGregor segment offers cargo and load handling solutions and maintenance services. Cargotec Corporation was incorporated in 2005 and is headquartered in Helsinki, Finland.
Full CYJBY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.